# Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study

> **NCT01046253** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 50 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Lansoprazole
- **DRUG:** Prevacid®

## Key facts

- **NCT ID:** NCT01046253
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2010-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01046253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01046253, "Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01046253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*